
BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Thamm, Douglas H., V.M.D.	POSITION TITLE		
eRA COMMONS USER NAME DTHAMM7	Assistant Professor of Oncology		
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Pennsylvania, Philadelphia, PA	B.A.	1990	Biology
University of Pennsylvania, Philadelphia, PA	V.M.D.	1995	Veterinary Medicine

A. Positions and Honors.

Positions and Employment

- 1995-1996 Intern, Small Animal Medicine/Surgery. Red Bank Veterinary Referral Service, Red Bank, NJ.
1996-1999 Oncology Residency. School of Veterinary Medicine, U. of Wisconsin – Madison, Madison, WI.
1999-2001 Postdoctoral Fellowship (Laboratory of Dr. E. Gregory MacEwen).
School of Veterinary Medicine, U. of Wisconsin – Madison, Madison, WI.
2001-2002 Consultant in Oncology. U. of Queensland School of Veterinary Science, Brisbane, Australia.
2002-2004 Assistant Scientist. School of Veterinary Medicine, U. of Wisconsin – Madison, Madison, WI.
2004-present Assistant Professor, Oncology, Department of Clinical Sciences, Colorado State University, Fort Collins, CO.

Other Experience and Professional Memberships

- 1999 Diplomate, American College of Veterinary Internal Medicine (Oncology subspecialty).
2003-2004 Associate Member, Comprehensive Cancer Center, U of Wisconsin – Madison, Madison, WI.
2005-present Member, Cell and Molecular Biology Graduate Program, Colorado State University.
2005-present Member, University of Colorado Comprehensive Cancer Center.
2006-present Member, Editorial Board, Veterinary and Comparative Oncology.
2006-present Member, Scientific Advisory Board, MBC Pharma Inc.

Honors

- 2000 Travel Award, AACR Molecular Biology in Clinical Oncology Workshop. Aspen, CO.
2004 E. Gregory MacEwen Young Investigator Award from the Veterinary Cancer Society.
2007 Pfizer Research Award from Colorado State University

B. Selected peer-reviewed publications (from 39 published or in press).

1. Thamm DH, Vail DM. Preclinical trial of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. **Am J Vet Res** 59: 286-289, 1998. **PMID: 9522946**
2. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double blind clinical trial using a canine model. **Clin Cancer Res** 4: 1567-1572, 1998. **PMID: 9626479**
3. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor: 41 cases (1992-1997). **J Vet Intern Med** 13: 491-497, 1999. **PMID: 10499735**
4. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a six-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. **J Vet Intern Med** 16: 704-709, 2002. **PMID: 12465768**
5. Poirier VJ, Thamm DH, Kurzman ID, Jeglum KA, Chun R, Obradovich JE, O'Brien MG, Fred III RM, Phillips BS, Vail DM. Liposome encapsulated doxorubicin (Doxil[®]) and doxorubicin in the treatment of vaccine associated sarcoma in cats. **J Vet Intern Med** 16: 726-731, 2002. **PMID: 12465772**

6. Thamm DH, MacEwen EG, Phillips BS, Hershey AE, Burgess KM, Pettit GR, Vail DM. Preclinical study of dolastatin-10 in dogs with spontaneously arising tumors. **Cancer Chemother Pharmacol** 49: 251-255, 2002. **PMID: 11935218**
7. Marr AK, Thamm DH, Kurzman ID, Vail DM, MacEwen EG. In vitro effects of 2-methoxyestradiol on canine tumor cells. **Vet Compar Oncol** 1(3): 159-167, 2003.
8. Thamm DH, Kurzman ID, MacEwen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT. Lipid-complexed intralesional cytokine / superantigen immunogene therapy for spontaneous canine tumors. **Cancer Immunol Immunother** 52: 473-480, 2003. **PMID: 12768328**
9. MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, Thamm DH, Radinsky R. C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. **Clin Exp Metastasis** 20(5): 421-430, 2003. ***Corresponding author. PMID: 14524531*
10. Poirier VJ, Huelsmeyer MK, Kurzman ID, Thamm DH, Vail DM. The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro. **Vet Compar Oncol** 1(4): 207-215, 2004.
11. Ma Y, Manolache S, Denes FS, Thamm DH, Kurzman ID, Vail DM. Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. **J Biomaterials Sci, Polymer Ed** 15(8): 1033-1047, 2004. **PMID: 15461188**
12. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, Wilson M, Radinsky R. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. **J Cell Biochem** 92(1): 77-91, 2004. *** Corresponding author. PMID: 15095405*
13. Katayama R, Huelsmeyer MK, Kurzman ID, Thamm DH, MacEwen EG, Vail DM. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. **Cancer Chemother Pharmacol** 54(1): 25-33, 2004. **PMID: 15108021**
14. Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. **Clin Cancer Res** 11(13): 4827-4834, 2005. **PMID: 16000580**
15. MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? **J Vet Intern Med** 19(5): 732-736, 2005. **PMID: 16231719**
16. Mullins MN, Dernell WS, Withrow SJ, Ehrhart EJ, Thamm DH, Lana SE. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998 – 2004). **J Am Vet Med Assoc** 228(1): 91-95, 2006. **PMID: 16426175**
17. Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, MacEwen EG. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. **Res Vet Sci** 81(1): 76-86, 2006. **PMID: 16256156**
18. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. **J Vet Med Sci** 68(6): 581-587, 2006. **PMID: 16820715**
19. U'ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor lysate vaccine in dogs with hemangiosarcoma. **J Vet Intern Med** 21: 113-120, 2007. **PMID: 17338158**
20. Saba CF, Thamm DH, Vail DM. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma. **J Vet Intern Med** 21: 127-132, 2007. **PMID: 17338160**
21. Kamstock D, Elmslie R, Thamm DH, Dow SW. Pilot study of xenovaccination against VEGF for inhibition of tumor growth and angiogenesis in canine soft tissue sarcoma. **Cancer Immunol Immunother** 56(8): 1299-1309, 2007. **PMID: 17502972**
22. Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail DM. hGM-CSF DNA cationic-lipid complexed autologous tumor cell vaccination in the treatment of canine B-cell multicentric lymphoma. **Vet Compar Oncol** 5(4): 219-231, 2007.
23. Reiser H, Wang J, Watkins, WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang G, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail DM, Thamm DH, Jeraj R, Tumas DB. GS-9219 – a novel prodrug of the acyclic nucleoside phosphonate PMEG with potent anti-neoplastic activity in human hematopoietic tumor cell lines and in dogs with spontaneous non-Hodgkin's lymphoma. **Clin Cancer Res** 14(9): 2824-2832, 2008. **PMID: 18451250**

24. Thamm DH, O'Brien MG, Vail DM. Effect of serum vascular endothelial growth factor on postsurgical outcome in dogs with osteosarcoma. **Vet Compar Oncol** 6(2): 1206-132, 2008.
25. Ptitsyn A, Weil M, Thamm DH. Systems biology approach to identification of biomarkers for metastatic progression in cancer. **BMC Bioinformatics** 9 (Suppl 9): S8, 2008. **PMID: 18793472**
26. Rebhun R, Charles B, Ehrhart EJ, Lana SE, Thamm DH. Prognostic and comparative analysis of survivin expression in untreated and relapsed canine lymphoma. **J Vet Intern Med** 22: 989-995, 2008. **PMID: 18647159**
27. Kow K, Thamm DH, Terry J, Bailey S, Withrow SJ, Lana SE. Impact of telomerase status on canine osteosarcoma patients. **J Vet Intern Med**, *in press* 2008. **PMID: 18761602**

C. Research Support (no overlap with current proposal)

Ongoing Research Support

Multiple Sponsors Thamm (PI or Co-PI) Ongoing

Canine Cancer Clinical Trials

A variety of studies are ongoing evaluating novel antineoplastic agents in early-stage clinical trials in dogs with a variety of neoplasms, including osteosarcoma, melanoma, non-Hodgkins lymphoma, multiple myeloma and others. These are sponsored by a number of human and veterinary pharmaceutical / technology companies, including Pfizer, Varian Systems, Gilead Sciences, Pharmacyclics, and EnGenelC.

CHF 778 B. Biller (PI) 08/2007-07/2009

American Kennel Club

Role of Regulatory T Cells in Osteosarcoma

The goal of this study is to investigate the number and function of regulatory T cells in tumor-draining lymph node and peripheral blood in dogs with osteosarcoma, and their modulation with chemotherapy.

Role: Co-Investigator

Charitable Giving Office of Kindy French, Inc. Thamm (PI) 12/2007-11/2008

Bisphosphonate-Targeted Chemotherapy to Treat Osteosarcoma Pain

This is a pilot/phase-I clinical trial evaluating MBC-11, a novel bisphosphonate/chemotherapy conjugate in dogs with spontaneous osteosarcoma.

CSU College Research Council E. Ehrhart (PI) 06/2007-05/2009

2-Deoxy D-Glucose as Therapy for Hypoxic Tumor Cells in Canine Osteosarcoma

This *in vitro* study is investigating the antiproliferative and cytotoxic effects of the glucose analog 2-DG in canine osteosarcoma cell lines, and attempting to correlate drug efficacy with glucose transporter expression.

Role: Co-I

CHF-1064-A R. Rebhun (PI) 01/2008-12/2008

American Kennel Club

Immunocytochemical Detection and siRNA-Mediated Knockdown of Survivin in Canine Lymphoma

The goal of this study is to determine if survivin expression can be assessed immunocytochemically in canine lymphoma samples, and to determine the phenotypic effect of survivin knockdown in canine lymphoma cells.

Role: Co-PI/Mentor

CSU Cancer Supercluster Thamm (Co-PI) 03/2008-02/2009

Polymer-Modified Nanoparticles for In Vivo Image-Guided Cancer Intervention

This study seeks to validate novel polymer-modified gadolinium nanoparticles co-synthesized with a fluorescent tag, chemotherapeutic agent and targeting moiety *in vitro* for targeting, cytotoxicity, and fluorescent and MRI imaging capability.

CSU Cancer Supercluster Duval (PI) 03/2008-02/2009

Generation of Caninized Monoclonal Antibodies for Cancer Treatment

